Sanofi's Cell-Based Flu Shot in Phase 1
Posted on: Tuesday, 26 September 2006, 12:01 CDT
Sanofi pasteur said Tuesday it began a phase 1 trial of a seasonal flu vaccine produced using cell culture technology.
The company hopes the cell culture production technique will provide a faster way of making flu vaccines than the current method that uses chicken eggs.
Sanofi said the trial is the first step towards filing a biologics license application for the vaccine.
The phase 1 trial will involve 100 healthy adults between the ages of 18 and 64. Half will receive the cell-based vaccine and half will receive an egg-based vaccine.
The trial is part of a contract Sanofi was awarded from the U.S. Department of Health and Human Services intended to accelerate the development of a cell culture-based flu shot.
Source: United Press International
Related Articles
- VaxInnate to Present Positive Results From Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting
- Iomai's Adjuvant Patch With Flu Vaccine Meets Trial Endpoint
- Ichor Melanoma Vaccine Clinical Trial Moves to Highest Dose Level
- Drug Maker Begins Trials on Bird Flu Vaccines in Humans
- Netherlands Begins Vaccination of Chickens Against Bird Flu
- New Vaccines Necessary for New Bird Flu Strain: U.S. Official
- Rotavirus Vaccines Pass Trials
- 43 Tons of Chinese Vaccines Help Vietnam Combat Bird Flu
- Biosecurity, Vaccine Screenings Prioritized Against Bird Flu in Indonesia
- Australian firm to start trials of bird flu vaccine
 |
 |
User Comments (0)
RSS Feeds